This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

JNJ-64041757

Johnson & Johnson

Drug Names(s): JNJ-757, JNJ64041757, ADU-214, ADU214

Description: ADU-214 was developed using Aduro's proprietary Live Attenuated Double-Deleted (LADD) method of engineering Listeria mononcytogenes bacteria into therapeutic agents that stimulate targeted immune response to specific tumor antigens.

Deal Structure: Aduro and Janssen
In October 2014, Aduro announced that it has entered into its second agreement with Janssen Biotech granting an exclusive, worldwide license to certain product candidates engineered for the treatment of lung cancer and certain other cancers based on its novel LADD immunotherapy platform. Under the agreement, Aduro will receive a $30 million up-front payment and is eligible to receive significant development, regulatory and commercialization milestone payments up to a potential total of $817 million. In addition, Aduro is eligible to receive high single-digit to double-digit tiered royalties on worldwide net sales upon successful launch and commercialization.

Under the agreement, Janssen will have exclusive rights to develop and commercialize LADD product candidates in lung cancer and will assume responsibility for all research, development, manufacturing, regulatory and commercialization activities for the licensed products. Aduro may provide...See full deal structure in Biomedtracker

Partners: Aduro Biotech


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug